Search

Displaying results 5331 - 5340 of 7180 in total
  1. Drug

    CYC116

    go.drugbank.com/drugs/DB05198
    Investigational

    Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition

  2. Drug

    Diphenidol

    go.drugbank.com/drugs/DB01231
    ApprovedWithdrawn

    Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children.

  3. Drug

    Radotinib

    go.drugbank.com/drugs/DB12323
    Investigational

    Radotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

  4. Drug

    Lemuteporfin

    go.drugbank.com/drugs/DB04980
    Investigational

    Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.

  5. Drug

    FK352B

    go.drugbank.com/drugs/DB06484
    Experimental

    FK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.

  6. Drug

    Mequitazine

    go.drugbank.com/drugs/DB01071
    Investigational

    It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.

  7. Drug

    Indopan

    go.drugbank.com/drugs/DB01446
    ExperimentalIllicit

    Indopan (alpha-methyltryptamine) is a stimulant and psychoactive drug which produces effects similar to 3,4-methylenedioxy-N-methylamphetamine (MDMA), despite being structurally dissimilar. … It was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, indopan became regulated as a Schedule I controlled substance in the United states.

  8. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.

  9. Drug

    Col-118

    go.drugbank.com/drugs/DB05778
    Investigational

    It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue.

  10. Drug

    Adlinacogene civaparvovec

    go.drugbank.com/drugs/DB16788
    Investigational

    It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX. … [L46711] Developed by Sangamo Therapeutics Inc., it is being investigated for the treatment of hemophilia B.[L46706]